Related Experiment Video

Updated: Jun 13, 2026

Operation Procedure and Precautions of Thread-Embedding Acupuncture Therapy in Alzheimer
05:54

Operation Procedure and Precautions of Thread-Embedding Acupuncture Therapy in Alzheimer

Published on: May 10, 2024

Combination treatments in Alzheimer's disease: risks and benefits

Tomasz Sobow1

  • 1Department of Old Age Psychiatry and Psychotic Disorders, Medical University of Lodz, Czechoslowacka 8/10, Lodz, Poland. tomasz.sobow@umed.lodz.pl

Expert Review of Neurotherapeutics
|April 28, 2010
PubMed

Insights

New Alzheimer's disease treatments are needed. Combining existing medications or adding novel compounds may improve cognitive function and modify disease progression, but requires precise patient selection and further trials.

Area of Science:

  • Neuroscience and Pharmacology
  • Alzheimer's Disease Therapeutics

Background:

  • Current Alzheimer's disease (AD) medications target late-stage neurotransmission, offering modest efficacy.
  • Novel therapeutic strategies are required to enhance treatment outcomes for cognitive deficits in AD.
  • Combination therapies and disease-modifying agents represent promising avenues for improved AD management.

Purpose of the Study:

  • To explore the potential of combination therapies for Alzheimer's disease.
  • To investigate the addition of non-neurotransmitter-based compounds for disease progression modification.
  • To highlight insights gained from recent add-on therapy studies in AD.

Main Methods:

  • Review of recent studies on add-on therapies in Alzheimer's disease.
  • Analysis of strategies involving drug combinations with different modes of action.
  • Consideration of non-symptomatic, non-neurotransmitter-based compounds.

Main Results:

  • Combination therapies may boost clinical effects compared to monotherapy.
  • Add-on treatments offer potential for disease progression modification.
  • Recent studies underscore the need for precise subject characterization using biomarkers.

Conclusions:

  • Combination therapy, including memantine with cholinesterase inhibitors, warrants further investigation.
  • Precise patient stratification with biomarkers is crucial for optimizing add-on therapy efficacy.
  • Future trials must address varying disease stages, comorbidities, and concomitant medications.

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...